- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin
This study is looking at a new combination medicine, CagriSema, for people with type 2 diabetes. We want to see how well it helps control blood sugar and manage weight, alongside their usual insulin and other diabetes medicines.
For: Type 2 diabetesSlovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes inadequately controlled on diet and exercise.
This study is testing a new combination medicine for people with type 2 diabetes who haven't fully managed their blood sugar with diet and exercise. It looks at how well the medicine works to lower blood sugar and help with weight loss over 40 weeks.
For: Type 2 diabetesItaly · Hungary · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity and type 2 diabetes
This study is testing a new weekly injection combining two medicines, cagrilintide and semaglutide (called CagriSema), for people with type 2 diabetes who are also overweight or obese. It aims to see how well it helps with weight loss and managing blood sugar.
For: Overweight and obesity and type 2 diabetesIreland · Hungary · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
This study is testing a new combination medicine, CagriSema, for people with type 2 diabetes. It's looking at whether this combined medicine is better at controlling blood sugar and helping with weight loss than existing treatments, including its individual components, semaglutide and cagrilintide.
For: Type 2 diabetesDenmark · Sweden · Slovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
For: Chronic Kidney Disease · Type 2 diabetesSpain · Hungary · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) once-weekly in participants with overweight or obesity
This study is looking at a new combination medicine, CagriSema, for adults who are overweight or have obesity. It wants to see if this weekly injection helps people lose weight and if it's safe to use. Researchers hope it can lead to meaningful weight loss.
For: ObesityFrance · Germany